---
title: "RougeTx Launches With $58M Series A for Rare Vascular Disease"
description: "RougeTx launched with $58 million to advance a potential disease-modifying treatment for hereditary hemorrhagic telangiectasia and expand its vascular-biology platform."
date: 2026-10-06T00:00:00.000Z
source: https://venturecapitaltracker.com/2026-rougetx-58m-series-a-hht
---

# RougeTx Launches With $58M Series A for Rare Vascular Disease

> RougeTx launched with $58 million to advance a potential disease-modifying treatment for hereditary hemorrhagic telangiectasia and expand its vascular-biology platform.

RougeTx has launched with a **$58 million Series A** to advance a potential disease-modifying treatment for hereditary hemorrhagic telangiectasia (HHT), a rare inherited bleeding disorder.

The round was co-led by BioGeneration Ventures, Angelini Ventures and Kurma Partners, with participation from Epidarex Capital, Vesalius Biocapital Partners, ROM Utrecht Region, p53 Invest and Kerna Ventures. An EIB co-investment facility also supports the financing through Angelini Ventures.

## What RougeTx is targeting

RougeTx is focused on vascular instability linked to pericyte dysfunction. Its lead program is intended as a once-daily oral treatment for HHT, while the company's periSCOPE platform is designed to identify additional diseases where restoring vascular stability could be therapeutically useful.

## Why the Series A is notable

The company is entering the market with a large early-stage round before clinical proof. That is typical of platform biotech only when investors believe the underlying biology can support more than one asset.

The main milestones are therefore scientific: preclinical validation, toxicology, manufacturing readiness and a credible path into first-in-human studies. If the HHT program works, the platform claim becomes more valuable; if it fails, the breadth of the periSCOPE thesis will be tested quickly.

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.